DRG Market Assessment 보고서

Seven premium-priced therapies—Avastin, Erbitux, Vectibix, Zaltrap, Stivarga, Lonsurf, and Cyramza—are approved in the United States for metastatic colorectal cancer. Therefore, medical…

Genomic aberration status, histology, performance status, and stage of disease are key factors that influence the treatment of non-small-cell lung cancer (NSCLC). The characterization of biomarker-…

Non-alcoholic steatohepatitis (NASH) is a common liver disease that can progress to liver fibrosis, cardiovascular disease, and cancer. In the absence of any approved treatments for it, there is a…

Hepatitis C virus (HCV) is the leading cause of end-stage liver disease and hepatocellular carcinoma in China and South Korea. The prevalence of this chronic disease remains high owing to the…

Acromegaly is a chronic endocrine disorder characterized by hypersecretion of growth hormone and overproduction of insulin-like growth factor-1. Nearly all cases of acromegaly are caused by an…

The regulatory and market access environment for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, staying ahead of the similarities and…

In the last ten years, TNF-α inhibitors have transformed the treatment of axial spondyloarthritis, including ankylosing spondylitis and nonradiographic axial spondyloarthritis, and have brought…

Due to rising antibiotic resistance rates, powerful antibiotics historically reserved for later lines of therapy are becoming standard-of-care treatment for gram-negative infections (GNIs),…

LaunchTrends: Venclexta (Wave 1) is the first in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched chronic…

Sickle cell disease (SCD) is a genetic disorder characterized by abnormality in the oxygen-carrying protein hemoglobin. The gene mutation underlying the disease results in the amino acid valine…

Asthma treatment generally includes rescue therapy to relieve acute exacerbations and maintenance therapy to prevent future attacks. A wide array of well-established therapies spanning multiple…

Parkinson’s disease (PD) treatment is complex; the disease is heterogeneous, requiring individualized treatment and frequent adjustments (e.g., in dosing, in regimens) to achieve symptom control…